Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Hellmann

Showing results (171-180 of 196) with videos related to

Pageof 20
Sort By:
Blood|October 7, 2000
Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trialT Robak, J Z Bloński, M Kasznicki, et al.
British Journal of Haematology|February 26, 2000
Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia - updated results of the multicentre study of 378 patientsT Robak, J Z Bloński, M Kasznicki, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 28, 2004
Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patientsJ Czyz, R Dziadziuszko, W Knopinska-Postuszuy, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 11, 2023
Intravenous immunoglobulin treatment for acute attacks in myelin oligodendrocyte glycoprotein antibody diseaseItay Lotan, John J Chen, Yael Hacohen, et al.
Leukemia|February 21, 2017
Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom studyA Hochhaus, T Masszi, F J Giles, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 2013
Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantationC Martínez, C Canals, B Sarina, et al.
Multiple Sclerosis and Related Disorders|July 25, 2025
Relapse and disability outcomes in incident MOGAD patients undergoing watchful waiting after onsetNanthaya Tisavipat, Adi Wilf-Yarkoni, Abdullah Al-Ani, et al.
Leukemia & Lymphoma|June 1, 1997
Activity of 2-chlorodeoxyadenosine (Cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low grade non-Hodgkin's lymphomaT Róbak, J Gora-Tybor, E Krykowski, et al.
Leukemia|March 5, 2004
Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III studyJ Holowiecki, S Grosicki, T Robak, et al.
Leukemia & Lymphoma|August 1, 1996
Intermittent 2-hour intravenous infusions of 2-chlorodeoxyadenosine in the treatment of 110 patients with refractory or previously untreated B-cell chronic lymphocytic leukemiaT Robak, M Błasinka-Morawiec, E Krykowski, et al.
Pageof 20

Showing results (171-180 of 196) with videos related to

Sort By:
Pageof 20
Blood|October 7, 2000
Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trialT Robak, J Z Bloński, M Kasznicki, et al.
British Journal of Haematology|February 26, 2000
Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia - updated results of the multicentre study of 378 patientsT Robak, J Z Bloński, M Kasznicki, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 28, 2004
Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patientsJ Czyz, R Dziadziuszko, W Knopinska-Postuszuy, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 11, 2023
Intravenous immunoglobulin treatment for acute attacks in myelin oligodendrocyte glycoprotein antibody diseaseItay Lotan, John J Chen, Yael Hacohen, et al.
Leukemia|February 21, 2017
Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom studyA Hochhaus, T Masszi, F J Giles, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 2013
Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantationC Martínez, C Canals, B Sarina, et al.
Multiple Sclerosis and Related Disorders|July 25, 2025
Relapse and disability outcomes in incident MOGAD patients undergoing watchful waiting after onsetNanthaya Tisavipat, Adi Wilf-Yarkoni, Abdullah Al-Ani, et al.
Leukemia & Lymphoma|June 1, 1997
Activity of 2-chlorodeoxyadenosine (Cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low grade non-Hodgkin's lymphomaT Róbak, J Gora-Tybor, E Krykowski, et al.
Leukemia|March 5, 2004
Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III studyJ Holowiecki, S Grosicki, T Robak, et al.
Leukemia & Lymphoma|August 1, 1996
Intermittent 2-hour intravenous infusions of 2-chlorodeoxyadenosine in the treatment of 110 patients with refractory or previously untreated B-cell chronic lymphocytic leukemiaT Robak, M Błasinka-Morawiec, E Krykowski, et al.
Pageof 20